By Sougato Das, President and COO, Life Science Nation (LSN)
The buzz among biotech execs and investors gathered at RESI JPM 2025 was if the last year of pharma deals falling to a decade-low was reversing with a rapid-fire source of new lower-risk drug candidates: China. With one-third of the therapeutic molecules bought by pharma coming from China last year, including the better-than-Pembro hopeful of Summit Therapeutics licensed from Chinese Akeso, US investors including Atlas, Bain, Forbion, General Atlantic and RTW are making major investments in Chinese biotech. Merck, Novartis, GSK, Gilead and other large pharmas have inked a slew of Chinese deals and have indicated they will do more, mainly in the areas of obesity, cardiovascular, immunology, liver diseases and oncology, many with novel MoAs. With relatively dry organic venture funding in China, Chinese companies are aggressively seeking Western suitors. China’s out-licensing is accelerating, with $46B in 2024, $38B in 2023 and $28B in 2022.
Of course, the first question is how is Summit’s drug candidate going to get FDA approval with Chinese-only studies? The strategy here is to reduce risk by licensing ‘biobetters’ that have shown clinical success in China and then running late-stage clinical studies in the US for approval. Chen Yu, formerly of Vivo Capital, was quoted as saying. “Why would we do any early-stage development in the U.S. anymore? Why wouldn’t we just get clinical PoC in China and then bring it over to the U.S. for the expensive clinical development when we actually know the drug works? …that could be a revolutionary new way for our industry to become more efficient.”
Not to be outdone, Merck announced it would license a competitive asset to Summit’s – and it was also from China.
Clinical trials in China can recruit faster than US-based trials with less cost, allowing a startup to go from formation to clinical trials in less than 18 months due to:
- Large populations that have not taken drugs for their disease are available at a multitude of regional hospitals
- Obtaining experimental drugs for free is a strong incentive for patients to enroll
- Less tightly regulated investigator-initiated trials are rapidly proliferating
- Regulatory flexibility and lesser fees/overhead
Investment and licensing is not the only Western-Chinese deal types being made. M&A has been on the rise. Examples include Genmab’s acquisition of ProfundBio ($1.8B) and BioNTech’s of Biotheus at ($950M).
With the speed of early-stage development in China, US startups may face new challenges. Alex Borisy, founder of Curie.Bio, cautioned that the usual process of publishing or presenting/postering at scientific meetings could “launch a thousand ships” in China, and advised early-stage biotechs to author patents in such a manner as to make it difficult to do so.
What could all this mean with a pro-tariff Trump presidency? That is TBD. However, Paul Hastings, CEO of Nkarta and former BIO Board Chair, remarked that it would be hard to imagine that raw materials and innovation would be exempted from future tariffs.
One of the best places to meet with early-stage Chinese companies is RESI. With Life Science Nation’s copious reach into the Chinese market, RESI conferences feature a multitude of attractive Chinese firms, eager to partner and pitch their technologies.
This article is a summary/digest of various general and biotech news articles; it is not original journalism.
When we think of a partnering conference like 
Targeted drug delivery has the potential to revolutionize cancer treatment, improving efficacy while reducing side effects. UPyTher is at the forefront of this innovation, leveraging its proprietary supramolecular drug delivery platform to enhance chemotherapy.
Next Phase Newsletter 